Please ensure Javascript is enabled for purposes of website accessibility

Better Coronavirus Play: Johnson & Johnson vs. Novavax

By Keith Speights - Feb 5, 2020 at 7:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Healthcare giant J&J and small biotech Novavax are both scrambling to develop coronavirus drugs. Which stock is the better pick?

Fears about the coronavirus outbreak that first hit China are increasing. There have been more than 20,000 confirmed cases of the virus and 425 deaths in just over one month.

But several drugmakers are racing to develop vaccines and antiviral drugs to fight the outbreak. Two companies at the forefront of these efforts are Johnson & Johnson (JNJ 0.52%) and Novavax (NVAX -4.90%). Which of these stocks is the better choice for investors?

Gloved hand holding a vial of blood with a label showing coronavirus and a check mark next to a positive sign

Image source: Getty Images.

The case for Johnson & Johnson

Johnson & Johnson announced on Jan. 29 that it's launching what the company calls "a multipronged response" to the threat presented by the 2019-nCoV coronavirus that's been making headlines. J&J's primary focus is to use its AdVac viral vector and PER.C6 cell line technology to develop a vaccine for 2019-nCoV.

This appears to be a smart step. Both AdVac and PER.C6 were used to create J&J's experimental Ebola vaccine. Even though the vaccine isn't approved yet, it's already being used in the Democratic Republic of the Congo and in Rwanda as part of those countries' campaigns to prevent the spread of Ebola. In addition, J&J used these two technologies to develop its experimental vaccines targeting HIV, respiratory syncytial virus (RSV), and Zika.

While J&J works as quickly as possible to develop a coronavirus vaccine, the company has donated bottles of its HIV drug darunavir/cobicistat, which is marketed under the brand name Prezcobix, to Chinese researchers investigating potential ways to treat the virus. Some anecdotal findings have suggested that HIV drugs could help patients with another coronavirus -- severe acute respiratory syndrome (SARS).

As a huge drugmaker, Johnson & Johnson also has a lot of drugs that are already on the market or in its pipeline, including quite a few antiviral drugs. The company plans to conduct research to see if previously tested drugs could potentially help patients fight the latest coronavirus strain.

Even if J&J's efforts are successful in addressing the coronavirus scare, though, sales of any one drug or vaccine would likely only amount to a drop in the bucket for the healthcare giant. But that underscores the appeal of buying J&J stock. The company offers a way to obtain diversification across the healthcare spectrum because of its multibillion-dollar business segments in consumer health, medical devices, and pharmaceuticals.

The case for Novavax

Novavax, on the other hand, would almost certainly see its shares skyrocket if it successfully develops a coronavirus vaccine. The biotech stock has already been one of the biggest winners among coronavirus-focused drugmakers, with its shares up over 60% year to date.

Developing vaccines is Novavax's specialty. The company's lead product is a nanoparticle-based vaccine for the flu. Novavax should report results from a late-stage study of this vaccine later in the first quarter of 2020. Its pipeline also includes three other experimental vaccines in clinical testing.

Novavax has already developed vaccines targeting other types of coronavirus -- SARS and Middle East respiratory syndrome. However, neither vaccine has won regulatory approval.

Gregory Glenn, Novavax's head of research and development, told Bloomberg that the company is "working very hard" on a coronavirus vaccine. However, he also acknowledged in another interview that it's not a quick process to develop a vaccine, win regulatory approval, and get to market.

Novavax has experienced some setbacks with its vaccine programs. The biotech's RSV vaccine ResVax failed in two different late-stage clinical studies. But past failures don't mean that future successes aren't possible. Novavax could emerge as a big winner with its experimental coronavirus vaccine or with its NanoFlu flu vaccine.

Better pick

If you're looking for the stock that would deliver the biggest returns if it's successful in developing a coronavirus vaccine or treatment, the answer is easy: Novavax. But that doesn't necessarily make Novavax the better pick over Johnson & Johnson. Why? There's no guarantee that Novavax will be successful with its coronavirus program.

For that matter, there's no guarantee that J&J will be successful with its coronavirus efforts, either. However, failure on this front simply won't matter that much to the investing case for J&J.

It's entirely possible that the current coronavirus worries will fade away, just as worries about the avian flu, Ebola, SARS, and other viruses aren't as great as they once were. Instead of buying a stock based only on the prospects for developing a coronavirus vaccine or therapy, the smarter approach is to buy a stock based on the prospects that it will deliver solid long-term gains.

Novavax might be able to generate tremendous gains in the future. However, the biotech's fortunes hinge largely on how NanoFlu performs in clinical testing. J&J's gains probably won't be jaw-dropping, but they should be more reliable. My view is that the stability and financial strength that J&J provides makes it the better choice for long-term investors.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$180.38 (0.52%) $0.94
Novavax, Inc. Stock Quote
Novavax, Inc.
$48.88 (-4.90%) $-2.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.